In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest From Joseph Haas

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval plus a move into first-line therapy.

Clinical Trials Business Strategies

Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts

Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.

Deal Watch Business Strategies

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.

Business Strategies Drug Approval Standards

Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition

BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

Business Strategies Leadership

Relmada Hopes Open-Label Efficacy, Safety Bolster Profile Of Depression Candidate

With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.

Clinical Trials Research & Development

Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First

With a Phase II study stopped for efficacy in bleeding reduction, Anthos hopes to bring abelacimab, a dual Factor XI/XIa inhibitor to market to prevent strokes in a-fib patients and to treat cancer patients with thrombosis.

Business Strategies Clinical Trials
See All
UsernamePublicRestriction

Register